细胞增殖特性与良性脑膜瘤复发的关系

目的 :探索良性脑膜瘤的复发与肿瘤细胞增殖能力的关系 ,并寻找能预测其复发的指标。　方法 :对 1 5例复发的良性脑膜瘤和 2 2例非复发的良性脑膜瘤共 4 9份标本分别进行增殖细胞核抗原 (PCNA)和Ki 6 7的免疫组化染色 ,计数阳性细胞数的比率即标记指数 (LI) ,比较各组间的PCNALI和Ki 6 7LI。　结果 :复发的良性脑膜瘤的PCNALI和Ki 6 7LI均显著高于未复发组 (P <0 .0 5 ) ;复发组中同一患者前后两次手术标本的PCNALI和Ki 6 7LI均无显著差异 (P >0 .0 5 )。　结论 :复发的良性脑膜瘤的细胞增殖性高于未复发组 ,当PCNALI>2 .0 %时 ,提示肿瘤有复发倾向。良性脑膜瘤复发后其增殖特性无明显改变     

Extrapulmonary and pulmonary small-cell carcinoma: Tumor biology,therapy, and outcome

Extrapulmonary small-cell cancer is a distinct clinicopathological entity from smallcell anaplastic carcinoma of the lung. Approximately 1,000 cases have been projected annually in the United States, which represents an overall incidence of between 0.1% and 0.4% of all cancer. Not surprisingly then, little information is available regarding the treatment of this disease, which presents a challenge to the clinician when it is regionally confined. The majority of patients with extrapulmonary small-cell neoplasms have only been treated with local modalities of therapy, surgery, radiation, or a combination of both. Prolonged survival is not infrequent, which is in contrast to the experience for small-cell lung cancer and surprising given our current systemic approach to patients with this disease. This report will summarize the similarities and differences in biology, natural history, and clinical characteristics of patients with extrapulmonary small-cell cancer and smallcell anaplastic carcinoma of the lung. The histogenesis of small-cell cancer is briefly reviewed. A general therapeutic approach to patients with small-cell lung cancer is reported. Lastly, recommendations for therapy of patients with regionally confined extrapulmonary small-cell cancer by primary site are outlined.     

跨矢状窦脑膜瘤术中矢状窦的处理

目的总结跨矢状窦脑膜瘤术中矢状窦的处理方法.方法对26例跨矢状窦脑膜瘤及受累矢状窦进行切除,依具体情况重建或不重建矢状窦.结果该组病人无手术死亡,手术后均未加重原有神经功能障碍,无脑血液回流障碍,7例重建矢状窦者未发现有矢状窦内血栓形成.结论矢状窦旁脑膜瘤的治疗除肿瘤切除外,对受累上矢状窦处理是否彻底对预防术后复发是至关重要的.对受累矢状窦应按具体情况按一定的原则进行积极处理.     

89例小脑幕脑膜瘤的显微外科手术治疗

目的 总结小脑幕脑膜瘤的手术治疗经验。方法 回顾分析1993年5月-2006年5月，89例经手术治疗的小脑幕脑膜瘤病人的临床表现、影像学检查、手术记录、病理及术后早期并发症。常见症状是头痛（54例，60．7％）、头晕（29例，32．6％）、步态异常（34例，38．2％）、听力损害（27例，30．3％）及面部疼痛（20例，22．5％）。主要体征是共济失调（38例，42．7％）、运动和感觉障碍（31例，34．8％）及脑神经损害（48例，53．9％）。多数病例MRI表现为等T1、T2信号并明显均一强化。结果 本组全切除65例（73．0％），次全切除23例（Okudera-KobayashiⅣ—Ⅴ级）。手术并发症的发生率和病死率分别为22．5％和1．1％。结论 根据小脑幕脑膜瘤部位以及与周围神经血管关系选择最佳手术入路。如全切肿瘤可能带来重要的神经功能损害，应考虑残留部分肿瘤。     

神经内镜辅助眶上锁孔入路治疗巨大嗅沟脑膜瘤

目的探讨神经内镜辅助眶上锁孔入路治疗巨大嗅沟脑膜瘤的手术效果及手术技巧。方法采用内镜辅助、眶上锁孔入路（显微手术）治疗12例巨大（≥7cm）嗅沟脑膜瘤。结果肿瘤全切除9例（SimpsonⅠ级切除5例，Ⅱ级切除4例），次全切除（SimpsonⅢ级切除）3例。无手术死亡。10例随访3个月～2年，平均14个月。9例恢复正常生活，1例生活能自理。NRI随访9例，肿瘤无复发。结论利用神经内镜辅助及显微外科技术，采用眶上锁孔入路、对肿瘤进行分块切除治疗巨大嗅沟脑膜瘤，手术创伤小，疗效满意。     

Anaplastic astrocytoma with eosinophilic granular cells

A 68‐year‐old man, who had no remarkable past medical history, was referred to a hospital because of disorientation and right‐sided hemiparesis. On magnetic resonance imaging, a contrast‐enhanced tumor in the left frontal lobe with perifocal edema was noted. He underwent left frontal lobectomy. Microscopic examination revealed infiltrative atypical astrocytes showing increased cellularity, distinct nuclear atypia, and many mitotic figures, while microvascular proliferation and necrosis were absent. Thus, the tumor was histologically diagnosed as anaplastic astrocytoma. It was of note that cytoplasmic eosinophilic granules were observed in approximately 25% of neoplastic cells. The granules were positively immunostained with anti‐αB‐crystallin antibody, and the other histochemical and immunohistochemical results also corresponded to Rosenthal fibers. The MIB‐1 labeling index of the highest area of the tumor was 22%, while that of granular cells was 2.1%. An ultrastructural study revealed amorphous electron‐dense structures attached to intermediate filament bundles, compatible with Rosenthal fibers. Such structures are relatively common in oligodendroglial tumors; however, they are extremely rare in astrocytic tumors. Fluorescence in situ hybridization targeted against chromosome 1 failed to demonstrate allelic loss of the short arm. The present case should also be discriminated from granular cell astrocytoma. We review related literature and discuss the significance of granules in gliomas.     

Anaplastic ganglioglioma with sarcomatous component: An immunohistochemical study and molecular analysis of p53 tumor suppressor gene

The present case report describes a case of ganglioglioma with a distinct sarcomatous component in the left temporal lobe of a 59‐year‐old Japanese man. Neoplastic neuroglial tissue contained both benign and anaplastic glial components with a MIB‐1 labeling index of 0.1% and 12.0%, respectively. Sarcomatous tissue adjacent to the anaplastic glial tissue was dominated by pleomorphic fibroblastic cells with a MIB‐1 labeling index of 10.8%. They were immunoreactive for smooth muscle actin, type IV collagen, and alpha 1 antitrypsin, but not for desmin and CD34. Interestingly, some of the sarcomatous cells were double‐positive for smooth muscle actin and GFAP. The p53 protein had accumulated in the anaplastic astrocytes and sarcomatous cells, but direct DNA sequencing of PCR products failed to detect any mutation in the p53 gene (from exon 4 to exon 10).     

嗅沟脑膜瘤术式选择及长期临床预后随访

目的分析嗅沟脑膜瘤的手术治疗和随访结果。方法收集20例嗅沟脑膜瘤手术病例,并分析其临床表现及随访结果。结果嗅沟脑膜瘤大多以精神症状、视觉障碍和嗅觉减退为首发症状,9例行冠状切口,4例行半冠状切口,分块切除肿瘤,5例翼点入路,1例纵裂入路。1例眶上入路,SimpsonI级切除6例。SimpsonⅡ级切除13例,SimpsonⅢ级切除1例,预后良好,1例复发。随访时间1~6年(平均3.1年),术前术后均保留嗅觉的为2例,精神状态改善18(91%)和视力障碍改善的15(75%)。1例(5%)复发再次手术。结论术式的选择取决诸多因素,预后取决于手术中的组织保护。     

Potential doubling time and tumour doubling time in meningiomas and neurinomas

Summary Cell kinetic study plays an important role in treatment planning of brain tumour patients. MIB-1 antibody has recently become available, which detects Ki-67 antigen even in the formalin-fixed paraffin-embedded specimens. We performed MIB-1 immunostaining in 50 meningiomas and 50 neurinomas, and estimated the cell cycle time (tc) and potential doubling time (Tpot) from MIB-1 staining index (MIB-1 SI) and mitotic index (MI). MIB-1 SI logarithmically correlated with MI in both meningiomas and neurinomas. The tc and the Tpot were expressed as a function of the mitosis time (tm), while the tm is known to be around one hour and not exceeding two hours. When the tm was assumed to be one hour, the average tcs of meningiomas and neurinomas were 6.53±3.56 days and 7.67±3.27 days, respectively. The Tpots were447 × (MIB-1 SI)^–1.29 × tm in meningiomas, and490 × (MIB-1 SI) ^–0.98 × tm in neurinomas.The tumour doubling times (Tds) were calculated from serial imaging studies in 22 neurinomas and 15 meningiomas. The Tds were formulated as794 × (MIB-1 SI) ^–0.83 in meningiomas and1380 × (MIB-1 SI) ^–0.97 in neurinomas. Most of the Tds correlated well with the Tpots in meningiomas and neurinomas, and exceeded values of the Tpot when the tm is assumed to be one hour, although a few tumours showed unexpectedly longer Tds. The Tpot and the tc estimated from MIB-1 SI and MI are clinically useful parameters for predicting the growth potential of meningiomas and neurinomas where no other simple methods are available.